Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania Hospital, Philadelphia, Pennsylvania.
Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania.
Fertil Steril. 2020 Oct;114(4):854-860. doi: 10.1016/j.fertnstert.2020.05.045.
To determine the rate of utilization, factors influencing the decision-making process, and patient satisfaction with preimplantation genetic diagnosis for monogenic disorders (PGT-M).
Survey study.
Academic center.
PATIENT(S): Genetically at-risk patients seen for PGT-M consultation between January 2010 and 2018.
INTERVENTION(S): Electronic survey including demographics, genetic history, consultation experience, decision-making process, and satisfaction with PGT-M process.
MAIN OUTCOME MEASURE(S): Rate of utilization of PGT-M, importance of decision-making factors, and satisfaction with PGT-M process.
RESULT(S): Among survey respondents (n = 49), the rate of utilization of PGT-M after consultation was 89.8%. Ninety-three percent of participants decided whether to pursue PGT-M within 3 months of consultation. Factors that were considered most important to this decision-making process included information provided at consultation, accuracy of test results after PGT-M, avoidance of suffering of an affected child, and ability to avoid termination of an affected pregnancy. Key barriers to utilization included financial burden and overall complexity of the in vitro fertilization (IVF)/PGT-M process. Of those utilizing PGT-M (n = 44), 72.1% had at least one live birth or were pregnant during the study period. Satisfaction with PGT-M was high, and most couples would use IVF/PGT-M for a future pregnancy (84.1%). Participants with a live birth were more satisfied with the PGT-M process than those who had no live birth.
CONCLUSION(S): Most patients seeking consultation for PGT-M were likely to pursue this technology despite financial burden and complexity of the process. Exploring factors that influence patient decision-making regarding PGT-M is important for tailoring the consultation and optimizing the overall experience.
确定单基因疾病胚胎植入前遗传学诊断(PGT-M)的利用率、影响决策过程的因素以及患者满意度。
调查研究。
学术中心。
2010 年 1 月至 2018 年期间因 PGT-M 咨询而具有遗传风险的患者。
电子调查,包括人口统计学、遗传史、咨询经验、决策过程以及对 PGT-M 过程的满意度。
PGT-M 的利用率、决策因素的重要性以及对 PGT-M 过程的满意度。
在接受调查的患者中(n=49),咨询后进行 PGT-M 的利用率为 89.8%。93%的参与者在咨询后 3 个月内决定是否进行 PGT-M。对这一决策过程最重要的因素包括咨询时提供的信息、PGT-M 后检测结果的准确性、避免患有遗传疾病的孩子的痛苦,以及避免终止患有遗传疾病的妊娠。利用率的主要障碍包括经济负担和体外受精(IVF)/PGT-M 过程的总体复杂性。在进行 PGT-M 的患者中(n=44),72.1%在研究期间至少有一次活产或怀孕。对 PGT-M 的满意度很高,大多数夫妇会在未来的妊娠中使用 IVF/PGT-M(84.1%)。有活产的参与者对 PGT-M 过程的满意度高于没有活产的参与者。
尽管存在经济负担和过程的复杂性,大多数寻求 PGT-M 咨询的患者仍可能选择这种技术。探讨影响患者对 PGT-M 决策的因素对于调整咨询和优化整体体验非常重要。